Patent intelligence · US
US 9636406
Method of treating cancer
Method of treating cancer
Patent details — US 9636406
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 2, 2017
- Expiration
- Apr 27, 2037
- Applicant
- Intensity Therapeutics, Inc.
- Claims
- 2
- CPC classes
- A61K, A61K2800/30, A61K2800/34, A61K2800/524
Quick answer
US 9636406 (Method of treating cancer) is held by Intensity Therapeutics, Inc.. Status: granted. Granted May 2, 2017. Expires Apr 27, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Intensity Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61K, A61K2800/30, A61K2800/34, A61K2800/524, A61K31/192, A61K31/20
More from Intensity Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 9636406?
US 9636406 (Method of treating cancer) is held by Intensity Therapeutics, Inc.. Status: granted. Granted May 2, 2017. Expires Apr 27, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9636406?
Intensity Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 9636406 expire?
Our index shows an expiration date of Apr 27, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.